Chinese biopharmaceutical company Innovent Biologics Inc (HKEX: 01801) announced on Wednesday that a phase 2 clinical study of picankibart (R&D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, has met its primary endpoint in Chinese patients with moderately to severely active ulcerative colitis (UC).
The multicentre, randomised, double-blind, placebo-controlled study aims to assess the efficacy and safety of picankibart for the treatment of moderately to severely active ulcerative colitis (modified Mayo score of 4 to 9 with an endoscopic subscore of greater than or equal to 2) comprising of induction and maintenance periods.
A total of 150 subjects were enrolled and randomized in a 1:1:1 ratio to receive intravenous infusion of placebo, picankibart 200 mg or picankibart 600 mg at weeks 0, 4 and 8 during the induction period. In the maintenance period, subjects received subcutaneous injection of picankibart 200 mg every 4 or 8 weeks.
Both the primary and secondary endpoints of the study were met. The primary endpoint was the proportion of subjects who achieved clinical remission (per modified Mayo score, defined as a rectal bleeding subscore of 0, a stool frequency subscore of less than or equal to 1, and an endoscopic sub-score of less than or equal to 1) at week 12 while secondary endpoints included the proportion of subjects who achieved clinical response, symptomatic remission, endoscopic remission or histologic-endoscopic mucosal remission compared to the placebo group.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline